Table 1. Anti-SARS-CoV-2 Activities of Pixatimod in Vero E6 Cells.
| SARS-CoV-2 isolate | assay method | EC50a (μg/mL) | CC50 (μg/mL) | selectivity indexa |
|---|---|---|---|---|
| VIC01 isolate | plaque reduction | 8.1 ± 3.1 (2.4–13.8)a | >236d ≫300e |
29 (>17 to >98a) |
| DE-Gbg20 isolate | plaque reduction | 2.7b (0.8–11.6c) | >87 | |
| cytopathic effect | 2.7b (0.8–11.6c) | >20 to >295 | ||
| QLD02 isolate | cytopathic effect | 13.2 (8.0–21.6) | >17 | |
| QLD935 isolate | cytopathic effect | 0.9 (0.4–1.9) | >200 |
a
Mean values, individual assay result ranges, and resulting selectivity index ranges in brackets.
b
Mean EC50 ± SE based on the data from three independent virus plaque reduction assays (PRNT50 values).
c
EC50 computed by the Reed and Muench formula based on the cytopathic effect assay. Range indicates upper (complete protection of cells) and lower (partial protection) limits of EC50 estimation.